# Sanguinarine (from Sanguinaria canadensis / Macleaya cordata)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/sanguinarine-from-sanguinaria-canadensis-macleaya-cordata
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Bloodroot alkaloid, 13-methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, Pseudochelerythrine, Sanguinarine (Sanguinaria canadensis and related Papaveraceae species), Sanguinaria canadensis alkaloid, SAG, Benzophenanthridine alkaloid

## Overview

Sanguinarine (C20H14NO4+) is a quaternary benzophenanthridine alkaloid that exerts [antimicrobial](/ingredients/condition/immune-support), anti-inflammatory, and preclinical anticancer effects through DNA intercalation, inhibition of NF-κB signaling, disruption of microbial membrane integrity, and induction of [autophagy](/ingredients/condition/longevity). In broiler animal models, dietary supplementation at 0.7 mg/kg reduced serum glucose, blood urea nitrogen, and uric acid (p<0.05) while lowering [pro-inflammatory cytokine](/ingredients/condition/inflammation)s TNF-α and IL-4 in jejunal mucosa, though no human clinical trial data exist to confirm equivalent effects in humans.

## Health Benefits

- **[Antimicrobial](/ingredients/condition/immune-support) Activity**: Sanguinarine inhibits fungal pathogens including Candida albicans with MIC values of approximately 100 μg/mL (93% inhibition) and demonstrates anti-tubercular effects against Mycobacterium species (IC50 ~9.61 μg/mL), likely through disruption of cell membrane integrity and inhibition of microbial enzymatic processes.
- **Anti-Inflammatory Effects**: In broiler jejunal mucosa, dietary sanguinarine at 0.7 mg/kg significantly reduced TNF-α and IL-4 concentrations (p<0.05), suggesting suppression of [pro-inflammatory cytokine](/ingredients/condition/inflammation) cascades mediated through NF-κB pathway modulation and downregulation of inflammatory gene expression.
- **[Gut Microbiome](/ingredients/condition/gut-health) Modulation**: Sanguinarine altered 14 operational taxonomic units (OTUs) in broiler gut flora, increasing 9 OTUs and favorably shifting the Firmicutes/Bacteroidetes ratio; Firmicutes OTU_3 showed a positive correlation with average daily gain, linking microbiome remodeling to host metabolic performance.
- **Antiangiogenic Potential**: Sanguinarine inhibits angiogenesis in a dose-dependent manner at nanomolar concentrations in preclinical models, potentially suppressing tumor vascularization by downregulating pro-angiogenic factors such as VEGF, though human data are entirely absent.
- **Preclinical Anticancer Activity**: In vitro and animal studies indicate sanguinarine induces [autophagy](/ingredients/condition/longevity) and apoptosis in cancer cell lines through multiple pathways; its salt and free-base forms are reported equipotent, and structural derivatives are under investigation to retain efficacy while reducing mutagenic liability.
- **Immune Enhancement**: Broiler studies demonstrated that dietary sanguinarine at ≥3.75 mg/kg significantly increased serum gamma globulin levels (p<0.01), indicating stimulation of humoral immune responses without adverse effects on total protein, albumin, or hepatic enzyme markers.
- **Metabolic Parameter Modulation**: In 56-day broiler trials, 0.7 mg/kg dietary sanguinarine lowered serum glucose, blood urea nitrogen, and uric acid at day 28 (p<0.05), suggesting improved nitrogen [metabolism](/ingredients/condition/weight-management) and glycemic regulation, though the translational relevance to human metabolic conditions has not been established.

## Mechanism of Action

Sanguinarine intercalates into double-stranded DNA due to its planar polycyclic ring structure, disrupting replication and transcription in both microbial and mammalian cancer cells; this intercalation also underlies its documented mutagenicity at high doses. At the cellular signaling level, it inhibits the NF-κB pathway, reducing transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s (TNF-α, IL-4) and anti-apoptotic proteins, thereby sensitizing transformed cells to programmed cell death via [autophagy](/ingredients/condition/longevity) induction. [Antimicrobial](/ingredients/condition/immune-support) activity is further mediated by destabilization of microbial plasma membranes and inhibition of bacterial enzymes, including [acetylcholine](/ingredients/condition/cognitive)sterase and certain bacterial topoisomerases, contributing to its broad-spectrum efficacy against fungi, mycobacteria, and gram-positive organisms. In the gut, sanguinarine acts as a selective antimicrobial modulator that reshapes microbial community composition—favoring Firmicutes taxa associated with improved nutrient absorption—while simultaneously dampening mucosal inflammatory signaling through downregulation of cytokine gene expression in intestinal epithelial and immune cells.

## Clinical Summary

No human clinical trials for sanguinarine supplementation have been published; all intervention data originate from controlled animal studies, primarily in broiler chickens. The most detailed trial used 0.7 mg/kg dietary sanguinarine over 56 days, measuring serum metabolites, jejunal cytokine profiles, and [gut microbiome](/ingredients/condition/gut-health) composition, with statistically significant improvements in [inflammatory](/ingredients/condition/inflammation) and metabolic markers (p<0.05) but without reporting effect sizes or confidence intervals. A secondary broiler study demonstrated immune enhancement (elevated gamma globulin, p<0.01) at ≥3.75 mg/kg with no adverse effects on hepatic or lipid panels, but small replicate-based sample designs limit generalizability. Until adequately powered Phase I/II human trials characterize pharmacokinetics, safe dosing windows, and efficacy endpoints, all health claims for sanguinarine in humans must be considered exploratory and unsupported by clinical-grade evidence.

## Nutritional Profile

Sanguinarine is a pharmacologically active alkaloid, not a nutrient, and contributes no meaningful macronutrient, micronutrient, or caloric value to the diet. As a quaternary ammonium benzophenanthridine (molecular formula C20H14NO4+, molecular weight ~332.33 g/mol), it is present at trace concentrations in whole plant material but is typically isolated and concentrated for research or commercial use; Sangrovit® extract is standardized to 1.5% sanguinarine by weight. It co-occurs with chelerythrine (C21H18NO5+) as the dominant alkaloid pair in M. cordata extracts, alongside minor phytochemicals including protopine, allocryptopine, sanguilutine, oxysanguinarine, coptisine, and homochelidonine, which may contribute to extract bioactivity through additive or synergistic mechanisms. Bioavailability data in humans are absent; oral absorption is suggested by animal studies, but the compound's cationic charge and planar aromatic structure may influence membrane permeability, tissue distribution, and metabolic stability in ways not yet characterized.

## Dosage & Preparation

- **Commercial Extract (Sangrovit®)**: Standardized to 1.5% sanguinarine from Macleaya cordata; used primarily in veterinary/agricultural applications; no approved human dosing established.
- **Ethanol Plant Extract**: Prepared from Sanguinaria canadensis or M. cordata roots/aerial parts at concentrations of 10–5000 μg/mL for in vitro bioassay applications; not standardized for human consumption.
- **Purified Alkaloid (Free Base or Salt)**: Salt and free-base forms are reported equipotent for [antimicrobial](/ingredients/condition/immune-support) and [autophagy](/ingredients/condition/longevity)-inducing activity; isolation yields up to 680.6 mg pure sanguinarine via Sephadex LH-20 and C-18 column chromatography.
- **Animal Feed Supplementation (Research Doses)**: 0.7–3.75 mg/kg diet in broiler studies for [microbiome](/ingredients/condition/gut-health), metabolic, and immune benefits; up to 5 mg/kg body weight/day in pigs with no observed toxicity.
- **Human Supplemental Dose**: Not established; no safe or effective human dose has been determined from clinical trial data; use without further safety characterization is not recommended.
- **Chromatographic Identification Standard**: TLC with CHCl3/MeOH/acetone solvent systems used for purity confirmation in research-grade preparations.
- **Timing**: Animal feeding studies administered continuously in diet over 28–56 days; no circadian or prandial timing data exist for human applications.

## Safety & Drug Interactions

Sanguinarine exhibits a bifurcated toxicity profile: oral LD50 in rats is 1658 mg/kg (relatively low acute oral toxicity), while intravenous LD50 is 29 mg/kg, indicating high systemic toxicity when administered parenterally, and the compound is documented as mutagenic at elevated doses, necessitating caution with prolonged or high-dose exposure. Historical use of sanguinarine in oral care products (e.g., Viadent® toothpaste) was associated with the development of oral leukoplakia—a potentially precancerous mucosal lesion—leading to regulatory concern and product reformulation, representing the most significant documented human safety signal. No formal drug interaction studies exist; however, given sanguinarine's inhibition of [NF-κB](/ingredients/condition/inflammation), DNA intercalation capacity, and potential modulation of cytochrome P450 enzymes, theoretical interactions with anticoagulants, immunosuppressants, and chemotherapeutic agents warrant investigation before any human use. Sanguinarine is contraindicated during pregnancy and lactation due to its mutagenic potential and lack of safety data; it should not be used by humans as a dietary supplement in purified form until Phase I clinical pharmacokinetic and safety trials establish tolerable dosing windows.

## Scientific Research

The evidence base for sanguinarine is dominated by in vitro assays and animal studies (primarily broiler chickens and rodent models), with no peer-reviewed human clinical trials identified in the available literature, placing the overall evidence quality at a preclinical level. Key animal studies include a 56-day broiler trial (n=6 replicates per group) demonstrating statistically significant reductions in serum glucose, BUN, and uric acid at 0.7 mg/kg dietary supplementation (p<0.05), as well as [gut microbiome](/ingredients/condition/gut-health) compositional shifts affecting 14 OTUs; however, effect sizes (e.g., Cohen's d) were not reported, limiting interpretation of clinical magnitude. Anti-tubercular activity was confirmed via bioassay-guided fractionation with IC50 values of 9.61 μg/mL against multiple Mycobacterium species, and antifungal efficacy against Candida albicans was documented at MIC ~100 μg/mL, both robust in vitro findings that lack confirmatory animal pharmacokinetic or human safety studies. Biotechnological research has advanced yield optimization using CRISPR/Cas9-mediated gene editing (58-fold sanguinarine yield increase via SMT gene modification), underscoring active interest in supply-chain development, but the overall clinical translation pipeline for sanguinarine in humans remains immature and speculative.

## Historical & Cultural Context

Sanguinaria canadensis, the primary botanical source of sanguinarine, has a well-documented history in Native American ethnomedicine, where the bright red-orange latex of bloodroot rhizomes was used as a dye, insect repellent, and topical [antimicrobial](/ingredients/condition/immune-support) agent by tribes including the Cherokee, Iroquois, and Ojibwe for treatment of skin conditions, warts, and respiratory ailments. In Traditional Chinese Medicine, Macleaya cordata (bo luo hui) has been employed for centuries as an [anti-inflammatory](/ingredients/condition/inflammation) and antimicrobial remedy, with preparations applied topically for skin infections and internally for digestive complaints. Early 20th-century Western herbal practice adopted bloodroot tinctures and poultices, and the compound gained renewed commercial attention in the 1980s when sanguinarine-containing toothpastes and oral rinses (e.g., Viadent®) were marketed for antiplaque and antigingivitis properties, though these were subsequently associated with oral leukoplakia and withdrawn from some markets. Biotechnological and pharmaceutical interest in sanguinarine has intensified in the 21st century, driven by its preclinical anticancer and antimicrobial profiles and the development of CRISPR/Cas9-enhanced production systems.

## Synergistic Combinations

Sanguinarine co-occurs naturally with chelerythrine in M. cordata and S. canadensis extracts, and these two benzophenanthridine alkaloids are believed to act synergistically on [antimicrobial](/ingredients/condition/immune-support) and [anti-inflammatory](/ingredients/condition/inflammation) targets, as evidenced by greater bioactivity of whole extracts compared to isolated fractions in some bioassay-guided studies; commercial preparations like Sangrovit® preserve this pairing. Preclinical research suggests that combining sanguinarine with conventional antibiotics or antifungals may produce additive or synergistic antimicrobial effects against resistant organisms such as Candida albicans and Mycobacterium species, though no formal combination index studies in humans have been conducted. The minor alkaloids present in whole-plant extracts—including protopine and allocryptopine—may modulate sanguinarine's bioavailability or receptor binding through entourage-type interactions, suggesting that standardized full-spectrum extracts could be pharmacologically superior to isolated sanguinarine for certain applications.

## Frequently Asked Questions

### What is sanguinarine used for?

Sanguinarine is primarily studied for its antimicrobial activity—demonstrating MIC values of ~100 μg/mL against Candida albicans and IC50 ~9.61 μg/mL against Mycobacterium species—as well as preclinical anticancer and anti-inflammatory effects. In animal feed research, it has been used at 0.7–3.75 mg/kg diet to modulate gut microbiome composition, reduce pro-inflammatory cytokines (TNF-α, IL-4), and enhance immune markers such as serum gamma globulin. No approved human therapeutic use exists, and all health applications remain investigational.

### Is sanguinarine safe for humans?

Sanguinarine has an oral LD50 of 1658 mg/kg in rats, suggesting moderate acute oral toxicity, but an intravenous LD50 of just 29 mg/kg indicates high systemic toxicity via non-oral routes. Historical use of sanguinarine in toothpastes was linked to oral leukoplakia, a potentially precancerous condition, and the compound is documented as mutagenic at high doses. Until human clinical pharmacokinetic and safety trials are completed, sanguinarine should not be used as a human dietary supplement in purified form.

### What plants contain sanguinarine?

Sanguinarine is primarily found in Sanguinaria canadensis (bloodroot), a North American woodland perennial whose rhizomes contain a bright red-orange latex rich in this alkaloid, and in Macleaya cordata (plume poppy), a Chinese native used extensively as the source for commercial sanguinarine extracts like Sangrovit®. Minor amounts also occur in other Papaveraceae family plants including Chelidonium majus (greater celandine) and Papaver somniferum. Biotechnological production via CRISPR/Cas9 gene editing of the SMT gene has achieved 58-fold yield increases in engineered plant systems.

### What is the effective dose of sanguinarine?

No safe or effective human supplemental dose has been established from clinical trials. In broiler animal studies, dietary doses of 0.7–3.75 mg/kg of feed produced significant anti-inflammatory, metabolic, and immunological effects over 28–56 days, and doses up to 5 mg/kg body weight per day showed no toxicity in pigs. Commercial Sangrovit® extract is standardized to 1.5% sanguinarine, but dosing recommendations for humans cannot be extrapolated from animal data without validated pharmacokinetic studies.

### Does sanguinarine have anticancer properties?

Sanguinarine exhibits preclinical anticancer activity in in vitro and animal models through multiple mechanisms, including DNA intercalation, NF-κB pathway inhibition, induction of autophagy, and antiangiogenic effects at nanomolar concentrations. Both the salt and free-base forms are reported equipotent in these assays, and structural derivatives are under investigation to improve the therapeutic index by reducing mutagenicity. However, no human clinical trials have evaluated sanguinarine's efficacy or safety as an anticancer agent, and it should not be used for cancer treatment outside of a controlled research setting.

### Does sanguinarine interact with common medications?

Sanguinarine may interact with medications metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP2D6, potentially altering drug efficacy or toxicity. Due to its antimicrobial properties and effects on cellular processes, concurrent use with immunosuppressants or antifungal medications should be discussed with a healthcare provider. Limited clinical data exists on specific drug interactions, making professional medical consultation essential before combining sanguinarine supplements with prescription medications.

### Is sanguinarine safe during pregnancy and for children?

Sanguinarine is not recommended during pregnancy due to insufficient safety data and its bioactive alkaloid nature, which may affect fetal development. Clinical evidence regarding pediatric safety is limited, and children should not use sanguinarine supplements without explicit guidance from a pediatrician. Both populations should avoid sanguinarine-containing supplements until robust safety studies establish appropriate use in these groups.

### What does current clinical research show about sanguinarine's antimicrobial effectiveness?

In vitro studies demonstrate sanguinarine's potent antimicrobial activity against Candida albicans (approximately 93% inhibition at 100 μg/mL) and anti-tubercular effects against Mycobacterium species with IC50 values around 9.61 μg/mL, primarily through disruption of microbial cell membranes. However, most evidence comes from laboratory studies rather than human clinical trials, limiting definitive conclusions about therapeutic effectiveness in living patients. Additional human studies are needed to translate these promising in vitro findings into practical clinical applications and determine optimal dosing for antimicrobial benefits.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*